CDEK by Data4ThePeople

Sign in Sign up

← All organizations

Acerta Pharma

For profitContributed to NME

Also known as: Acerta Clinical Trials | Acerta Pharma | Acerta Pharma, a member of the AstraZeneca Group | Acerta Pharma BV | Acerta Pharma B.V. | Acerta Pharma, LLC

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

First NDA

Last known activity

Mar 15, 2025

Acquired by AstraZeneca on Jan 1, 2015

Timeline

2010s

Jul 1, 2013
Acerta Pharma— Founded
Jan 1, 2015
AstraZeneca— Acquired By
Oct 31, 2017
acalabrutinib— NDA Organization
Oct 31, 2017
acalabrutinib— NDA Secondary Org

Drugs by trial phase (39 distinct, 54 trials)

Phase 3 (13 own, 0 via acquisition)

Phase 2 (15 own, 0 via acquisition)

Phase 1 (11 own, 0 via acquisition)

Marketed drugs (1)

acalabrutinib

Recent trials (50)

NCT06757647CollaboratorPhase 2Mar 15, 2025
NCT05495464CollaboratorEarly Phase 1Nov 18, 2022
NCT04529772Lead sponsorPhase 3Oct 8, 2020
NCT04497948Lead sponsorPhase 1Sep 21, 2020
NCT04402138CollaboratorPhase 2Jul 20, 2020
NCT04489797CollaboratorPhase 1Jul 20, 2020
NCT04488016CollaboratorPhase 1Jun 24, 2020
NCT04435483CollaboratorPhase 1May 22, 2020
NCT04380688CollaboratorPhase 2May 12, 2020
NCT04346199CollaboratorPhase 2Apr 24, 2020
NCT05140096Lead sponsorPhase 1Jan 3, 2020
NCT04008706Study directorPhase 3Aug 1, 2019
NCT03899337CollaboratorPhase 2Apr 30, 2019
NCT03836261Lead sponsorPhase 3Feb 25, 2019
NCT03736616CollaboratorPhase 2Nov 30, 2018

Details

Founded: San Carlos, CA, US Jul 1, 2013
First NDA: Oct 31, 2017
Last known activity: Mar 15, 2025

Designations held

Orphan drug
Priority review
Breakthrough therapy
Accelerated approval

Notes

Acquired by AstraZeneca in 2016